12 GHP Biotechnology & Lifesciences Awards 2026 Based in Suffolk, Quagilance is an independent pharmacovigilance quality assurance company that specialises in global PV compliance, audit, and quality oversight across the life sciences sector. The firm provides strategic quality assurance support to biotechnology, pharmaceutical, and advanced-therapy organisations, with a particular strength within complex, multi-vendor and multi-territory PV environments. Quagilance’s operations span the full PV lifecycle, and includes global vendor and partner audits, affiliate and system audits, qualitymanagement system assessments, inspection readiness, and targeted regulatory compliance reviews. Its clients range from early-stage and mid-sized biotechnology companies preparing for first approvals, through to established global pharmaceutical organisations requiring independent oversight of outsourced PV activities. Rather than providing operational PV services, Quagilance was intentionally positioned to sit outside day-to-day case processing, enabling the objective evaluation of systems, processes, and governance models. This focus was defined through extensive prior experience working within both sponsor organisations and service providers, where recurring gaps were observed in oversight, role clarity, escalation pathways, and the practical application of global PV regulations. “Through years of hands-on experience across Europe, the UK, North America, the Middle East, Asia-Pacific, and emerging markets, it became clear that regulatory non-compliance most often arises from fragmented responsibilities, poorly adapted ‘copy-paste’ procedures, and insufficient independent challenge of outsourced activities,” Ejaz told us. “Quagilance was therefore established to address this gap by providing pragmatic, risk-based quality assurance support that is grounded in real regulatory expectations rather than theoretical compliance models.” Ejaz Butt is a PVQA consultant boasting more than two decades of experience across the pharmaceutical and biotechnology sectors. He has supported organisations from early clinical development through to commercial readiness, completing more than 200 successful PV B As the life sciences sector becomes increasingly complex, the need for independent, specialist pharmacovigilance (PV) quality assurance (QA) is now crucial. This ensures that pharmaceutical products meet stringent safety and quality standards, safeguarding patient safety and public trust. Ejaz Butt is a globally renowned pharmacovigilance auditor and the bright mind behind leading PVQA consultancy Quagilance. We spoke with Ejaz below to learn more, as Quagilance is named in the Biotechnology and Lifesciences Awards 2026. audits around the world. Ejaz is an Honorary Fellowship Member of the Pharmaceutical Information and Pharmacovigilance Association, past President of PIPA, and a GVP committee member of the RQA. Quagilance operates as an independent specialist consultancy rather than a traditional multi-staff firm which, for Ejaz, was a deliberate choice and not a constraint. Where collaboration or additional capacity is required, the firm works selectively with a small network of highly experienced pharmacovigilance and quality assurance professionals. These individuals are engaged based on demonstratable regulatory expertise, and a shared commitment to integrity, objectivity, and patient safety. The firm further distinguishes itself through its exclusive focus on independent pharmacovigilance quality assurance combined with Ejaz’s hands-on global expertise. By not providing operational pharmacovigilance services, Quagilance maintains true independence and objectivity when assessing systems, processes, and governance models. Each engagement is grounded in how pharmacovigilance actually functions within the client’s environment, providing recommendations that are both regulator-aligned and operationally realistic. As an independent specialist consultancy, the priority for Quagilance remains delivering high-quality, regulator-aligned pharmacovigilance quality assurance support whilst adapting to the evolving needs of biotechnology and life sciences organisations. Looking to the future, the focus for 2026 is on consolidation, refinement, and selective growth over expansion for its own sake. A key area of focus for the firm will be the further development of structured, risk-based PV oversight frameworks that support organisations operating increasingly complex outsourced and hybrid models. Building on recent work, these frameworks will continue to integrate audit intelligence, contract review, governance assessment, and CAPA trending to help clients demonstrate sustained control and inspection readiness. Quagilance also plans to expand inspection-readiness and remediation support, particularly for biotechnology companies approaching first approvals or navigating post-inspection commitments. Additionally, it will continue developing mentoring and knowledge-sharing initiatives within the pharmacovigilance QA community, reflecting a longer-term commitment to supporting professional standards and consistency across the sector, particularly as demand for PVQA expertise continues to grow. Contact: Ejaz Butt Company: Quagilance Ltd Web Address: www.quagilance.com Leading Innovator in Life-Science Safety & Compliance 2026
RkJQdWJsaXNoZXIy MTUyMDQwMA==